GIS.DEライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (30 4月 2024 @ 00:35):

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally...

Stats
本日の出来高	6 898.00
平均出来高	960.00
時価総額	77.54B
EPS	€0 ( 2024-04-25 )
Last Dividend	€0.750 ( 2023-09-14 )
Next Dividend	€0 ( N/A )
P/E	14.84
ATR14	€0.153 (0.25%)

Gilead Sciences Inc 相関

10 最も正の相関

10 最も負の相関

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Gilead Sciences Inc 財務諸表

Annual	2023
収益:	€27.12B
総利益:	€20.62B (76.04 %)
EPS:	€4.54

FY	2023
収益:	€27.12B
総利益:	€20.62B (76.04 %)
EPS:	€4.54

FY	2022
収益:	€27.28B
総利益:	€21.62B (79.26 %)
EPS:	€3.66

FY	2021
収益:	€27.31B
総利益:	€20.70B (75.82 %)
EPS:	€4.95

Financial Reports:

No articles found.

Gilead Sciences Inc Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
€0.730 (N/A)	€0.730 (N/A)	€0.750 (N/A)	€0.750 (N/A)	€0.750 (N/A)	€0 (N/A)	€0 (N/A)	€0 (N/A)	€0 (N/A)	€0 (N/A)

Gilead Sciences Inc Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 6.87 - Stable (37.34%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	€0.430	2015-06-12
Last Dividend	€0.750	2023-09-14
Next Dividend	€0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	34	--
Total Paid Out	€20.74	--
Avg. Dividend % Per Year	0.00%	--
Score	4.47	--
Div. Sustainability Score	10.00
Div.Growth Potential Score	6.87
Div. Directional Score	8.78	--

Next Divdend (Est)
(2024-07-01)

€0.764 Estimate 22.27 %

Dividend Stability

0.59 Average

Dividend Score

4.47

Pay Frequency

Quarterly

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for XETRA

Symbol	Title	Last dividend	Frequency	Yearly Dividend
TTK.DE	Ex Dividend Junior	2023-05-25	Annually	0.00%
DWD.DE	Ex Dividend Junior	2023-07-28	Quarterly	0.00%
MZX.DE	Ex Dividend Knight	2023-06-08	Sporadic	0.00%
8TRA.DE	Ex Dividend Junior	2023-06-02	Annually	0.00%
XGR2.DE	Ex Dividend Junior	2023-06-08	Annually	0.00%
FPMB.DE	Ex Dividend King	2023-10-12	Quarterly	0.00%
PFE.DE	Ex Dividend Knight	2023-07-27	Quarterly	0.00%
ASME.DE	Ex Dividend Knight	2023-08-01	Semi-Annually	0.00%
HNR1.DE	Ex Dividend Junior	2023-05-04	Annually	0.00%
SDF.DE	Ex Dividend Junior	2023-05-11	Annually	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.209	1.500	5.82	8.73	[0 - 0.5]
returnOnAssetsTTM	0.0912	1.200	6.96	8.35	[0 - 0.3]
returnOnEquityTTM	0.260	1.500	8.22	10.00	[0.1 - 1]
payoutRatioTTM	0.672	-1.000	3.28	-3.28	[0 - 1]
currentRatioTTM	1.426	0.800	7.87	6.30	[1 - 3]
quickRatioTTM	1.057	0.800	8.49	6.79	[0.8 - 2.5]
cashRatioTTM	0.539	1.500	8.11	10.00	[0.2 - 2]
debtRatioTTM	0.402	-1.500	3.30	-4.94	[0 - 0.6]
interestCoverageTTM	8.06	1.000	8.13	8.13	[3 - 30]
operatingCashFlowPerShareTTM	6.42	2.00	7.86	10.00	[0 - 30]
freeCashFlowPerShareTTM	5.95	2.00	7.03	10.00	[0 - 20]
debtEquityRatioTTM	1.094	-1.500	5.62	-8.43	[0 - 2.5]
grossProfitMarginTTM	0.760	1.000	0.661	0.661	[0.2 - 0.8]
operatingProfitMarginTTM	0.280	1.000	6.39	6.39	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.320	1.000	9.33	9.33	[0.2 - 2]
assetTurnoverTTM	0.436	0.800	-0.424	-0.339	[0.5 - 2]
Total Score				10.70

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	14.50	1.000	8.64	0	[1 - 100]
returnOnEquityTTM	0.260	2.50	8.86	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	5.95	2.00	8.02	10.00	[0 - 30]
dividendYielPercentageTTM	4.59	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	6.42	2.00	7.86	10.00	[0 - 30]
payoutRatioTTM	0.672	1.500	3.28	-3.28	[0 - 1]
pegRatioTTM	0.690	1.500	8.73	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.295	1.000	5.12	0	[0.1 - 0.5]
Total Score				6.87

Gilead Sciences Inc

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.